Articles from ClearB Therapeutics, Inc.

ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that an abstract will be presented as a poster at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2025, taking place in Amsterdam, the Netherlands 7 – 10 May 2025.

ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that the company has licensed TQL-1055 from Adjuvance Technologies, Inc. TQL-1055 is a novel saponin-based adjuvant that will be combined with ClearB’s proprietary variants of HBsAg, CLB-405 and CLB-505. Pre-clinical data related to this therapeutic vaccine combination will be presented as posters at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024, taking place in San Diego, CA, 15 – 19 November 2024.

ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive a functional cure for Hepatitis B, announced today that two abstracts will be presented as posters at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2024, taking place in Milan, Italy 5 – 8 June 2024. In addition, one of the posters has been selected as a TOP presentation (see details below).

ClearB Therapeutics, Inc., now a clinical-stage biotechnology company committed to developing therapies to drive functional cure in patients with chronic hepatitis B (CHB) infection, announced that the first patient has been dosed in the Phase 1b clinical study evaluating the therapeutic vaccine CLB-3000 (ACTRN1263000841673). Satisfactory review of safety data for this patient supported opening enrollment for the remainder of the cohort.

ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that two abstracts were accepted for poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2023, taking place in Vienna, Austria June 21 - 24, 2023.

ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure in patients chronically infected with Hepatitis B, announced today that two abstracts were accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting, to be held in Washington, DC, USA, November 4 – 8, 2022.

ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract entitled ‘Therapeutic vaccination with CLB-3000 in a mouse model of chronic Hepatitis B induces anti-HBs responses associated with functional cure’ was accepted for poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2022, taking place in London, UK June 22 - 26, 2022.

ClearB Therapeutics, Inc., a company developing a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract titled “Impact of various expression systems on efficacy of HBsAg therapeutic vaccines to achieve clearance in a mouse model of chronic hepatitis B” was accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021, taking place virtually November 12-15, 2021.

ClearB Therapeutics, Inc., a company developing a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract entitled ‘A novel therapeutic vaccine achieves functional cure in a mouse model of chronic hepatitis B’ was accepted for poster presentation at the European Association for the Study of the Liver (EASL) Digital International Liver Congress (ILC), taking place virtually June 23-26, 2021. The poster was also selected for inclusion in the ‘Best of ILC’ summary, which highlights the most noteworthy scientific contributions at this year’s meeting.